author

Author: Don Obrien

Pharming Group reports financial results for the first nine months of 2021


Patient enrollment and product demand driving ongoing revenue recovery to US$52.9 million in Q3 2021

Operating profit impacted by upfront payment of US$ 13.1 million for the in-licensing of OTL-105.

Continued strong positive cash flow from operations enable increasing investment in the pipeline to support long-term growth

LEIDEN, The Netherlands, Oct. 28, 2021 /PRNewswire/ — Pharming Group N.V. (“Pharming” or “the Company”) (Euronext Amsterdam: PHARM/NASDAQ: PHAR) presents its preliminary (unaudited) financial report for the first nine months ended September 30, 2021.

Pharming Group N.V. logo (PRNewsfoto/Pharming Group N.V.)

Pharming Group N.V. logo (PRNewsfoto/Pharming Group N.V.)

Chief Executive Officer, Sijmen de Vries, commented
“We are pleased to deliver continued quarter-on-quarter revenue growth for the year to date, as expected, following the impact of COVID-19 on sales earlier in 2021, as a result of ongoing patient enrollment and increasing product demand. Supported by the strength of the underlying business; we are continuing to invest in future growth in line with our strategy to develop and expand our pipeline through leverage of our in-house expertise. This investment includes licensing of OTL-105, an investigational gene therapy for the potentially curative treatment of hereditary angioedema, from Orchard Therapeutics in July 2021.We are also investing significant and increasing amounts in preparation for the potential launch of leniolisib in Q4 2022, subject to regulatory approval.

I look forward to the read-out of the registration enabling study for leniolisib, expected early in the new year, as a product with transformational potential for APDS patient’s lives and also transformational commercial potential for Pharming.”

Operational highlights (Q3 2021)

  • Signed a strategic collaboration with Orchard Therapeutics, a global gene therapy leader, to research, develop, manufacture and commercialize OTL-105, a newly disclosed investigational ex-vivo autologous hematopoietic stem cell (HSC) gene therapy for the treatment of hereditary angioedema (HAE). OTL-105 is designed to increase C1 esterase inhibitor (C1INH) in HAE patient serum to prevent HAE attacks.

  • Entered into an exclusive license agreement with NewBridge Pharmaceuticals for the distribution of RUCONEST® in the Middle East and North Africa.

  • Topline results from two randomized, open label, controlled, pilot clinical trials of patients hospitalized with COVID-19 treated with RUCONEST® for the prevention of severe SARS-CoV-2 infection. Results from these studies support Pharming’s initial hypothesis on the need to control the hyper-inflammatory process in patients with severe COVID-19 infection. The results are being analyzed to design future clinical trials with RUCONEST® for the treatment of COVID-19 and non-COVID-19 conditions.

  • Continued significant investment in pipeline, including launch preparation for leniolisib, which is expected in Q4 2022, dependent on regulatory approval.

Financial Summary

Amounts in US$m except per share data

YTD 2021

YTD 2020

% Change

Income Statement

Revenues

146.1

151.9

(4)%

Gross profit

130.6

135.3

(3)%

Operating profit

15.3

57.7

(72)%

Profit for the year

13.9

28.9

(49)%

Balance Sheet

Cash & marketable securities

184.8

176.0

5%

Share Information

Basic earnings per share (US$)

0.022

0.045

(49)%

Diluted earnings per share (US$)

0.018

0.039

(51)%

Financial highlights

  • Total revenues increased by 6% from US$49.7 million in Q2 2021 to US$52.9 million in Q3 2021, as a result of the ongoing recovery in sales following the impact of COVID-19 on the US healthcare economy earlier in Q1 2021, as previously noted in the Company’s Q1 2021 and Q2 2021 financial reports. Revenues for the first nine months of 2021 were US$146.1 million, a 4% decrease compared to the first nine months of 2020 (US$151.9 million).

  • RUCONEST® sales in the US continued to recover during Q3 2021, with quarter-on-quarter revenues increasing by 6% to US$51.1 million (Q2 2021: US$48.4 million), driven by an increase in patient enrollment and product demand. For the first nine months of 2021, US sales amounted to US$141.1 million, a 3% decrease from US$145.9 million in the first nine months of 2020.

  • Revenues in Europe and RoW decreased to US$5.0 million for the first nine months of 2021 (9M 2020: US$6.1 million). In Q3 2021 revenue from Europe and RoW sales were US$1.9 million, an increase of 58% on Q2 2021 (US$1.2 million), mainly as a result of phasing of ordering.

  • Gross profit for the first nine months of 2021 was US$130.6 million a 3% decrease in comparison to the first nine months of 2020 (US$135.3 million). However, gross profit increased by 4% compared to Q2 2021, in line with the increased quarter-on-quarter revenues.

  • Operating profit for the first nine months of 2021 was US$15.3 million, decreasing 72% on the first nine months of 2020 (US$57.7 million). This was due to significant investments in the pipeline, including one- off costs of the upfront payment of US$13.1 million to in-license OTL-105 from Orchard Therapeutics in Q3 2021 and increased costs of corporate development, including costs associated with compliance and insurances as specified further below. Without the upfront payment for OTL-105 operating profit would have come to US$28.4 million, growing from US$17.3 million in H1 2021.

  • Other operating costs increased to US$116.4 million compared to US$78.5 million in the first nine months of 2020. The increase is due to investment in Pharming’s long-term growth, with increased R&D expenditure, the cost of the OTL-105 license (US$13.1 million), leniolisib pre-launch marketing preparations and manufacturing cost for leniolisib, an increase in employee numbers to support growth, a significant increase in cost of insurances due to Nasdaq listing, an increase in share-based compensation and increased compliance and control costs relating to the recent US Nasdaq listing, as previously noted in the Company’s Q1 2021 and Q2 2021 financial reports.

  • Net profit for the first nine months of 2021 was US$13.9 million, a 49% decrease compared to the first nine months of 2020 (US$28.9 million), as a result of initial in-licensing cost of OTL-105 (US$13.1 million) leading to lower operating profit which was offset by currency exchange rates and lower funding costs.

  • Cash and cash equivalents, together with restricted cash, decreased from US$206.7 million at the end of 2020 to US$184.8 million at the end of Q3 2021. This was as a result of positive cash flows from operating activities of US$21.9 million remaining after the US$ 13.1 million one- off payment to Orchard Therapeutics and reduced by investments and negative financing cash flows totaling US$42.9 million. These US$42.9 million include investments in production facilities and the payment of the final US$25.0 million milestone to Bausch Health Inc. in Q2 2021 in relation to the re-acquisition of the North American RUCONEST® commercialization rights in 2016.

Outlook

For the remainder of 2021, we expect:

  • Continued quarter on quarter increase in revenues from RUCONEST® sales due to normalizing pharmaceutical markets following the impact of COVID-19. However, we will continue to monitor the situation in all markets and could expect some periodic disruptions.

  • Maintenance of positive net earnings during the remainder of the year.

  • Significant and increasing investment in launch-critical medical affairs and pre-marketing activities for leniolisib as well as continued investment in ongoing clinical trials for rhC1INH and other development activities, including OTL-105.

  • Investments in acquisitions and in-licensing of new development opportunities and assets.

No further specific financial guidance for 2021 is provided.

About Pharming Group N.V.
Pharming Group N.V. is a global, commercial stage biopharmaceutical company developing innovative protein replacement therapies and precision medicines for the treatment of rare diseases and unmet medical needs.

The flagship of our portfolio is our recombinant human C1 esterase inhibitor (rhC1INH) franchise. C1INH is a naturally occurring protein that down regulates the complement and contact cascades in order to control inflammation in affected tissues.

Our lead product, RUCONEST®, is the first and only plasma-free rhC1INH protein replacement therapy. It is approved for the treatment of acute hereditary angioedema (HAE) attacks. We are commercializing RUCONEST® in the United States, the European Union and the United Kingdom through our own sales and marketing organization, and the rest of the world through our distribution network.

In addition, we are investigating the clinical efficacy of rhC1INH in the treatment of further indications, including pre-eclampsia, acute kidney injury and severe pneumonia as a result of COVID-19 infections.

We are also studying our oral precision medicine, leniolisib (a phosphoinositide 3-kinase delta, or PI3K delta, inhibitor), for the treatment of activated PI3K delta syndrome, or APDS, in a registration enabling Phase 2/3 study in the United States and Europe.

Additionally, we entered into a strategic collaboration with Orchard Therapeutics to research, develop, manufacture and commercialize OTL-105, a newly disclosed investigational ex-vivo autologous hematopoietic stem cell (HSC) gene therapy for the treatment of HAE.

Furthermore, we are leveraging our transgenic manufacturing technology to develop next-generation protein replacement therapies, most notably for Pompe disease, which is currently in preclinical development.

Risk profile
The risks outlined in the 2020 Annual Report continued to apply in the first nine months of 2021 and are expected to apply for the rest of the financial year.

We continue to closely monitor the key risks and opportunities, and will respond appropriately to any emerging risk.

Related party transactions
There are no material changes in the nature, scope, and (relative) scale in this reporting period compared to last year.

Auditor’s involvement
The Condensed Consolidated Interim Financial Statements have not been audited by the Company’s statutory auditor.

Forward-looking Statements
This press release contains forward-looking statements, including with respect to timing and progress of Pharming’s preclinical studies and clinical trials of its product candidates, Pharming’s clinical and commercial prospects, Pharming’s ability to overcome the challenges posed by the COVID-19 pandemic to the conduct of its business, and Pharming’s expectations regarding its projected working capital requirements and cash resources, which statements are subject to a number of risks, uncertainties and assumptions, including, but not limited to the scope, progress and expansion of Pharming’s clinical trials and ramifications for the cost thereof; and clinical, scientific, regulatory and technical developments. In light of these risks and uncertainties, and other risks and uncertainties that are described in Pharming’s 2020 Annual Report and the Annual Report on Form 20-F for the year ended December 31, 2020 filed with the U.S. Securities and Exchange Commission, the events and circumstances discussed in such forward-looking statements may not occur, and Pharming’s actual results could differ materially and adversely from those anticipated or implied thereby. Any forward-looking statements speak only as of the date of this press release and are based on information available to Pharming as of the date of this release.

Inside Information
This press release relates to the disclosure of information that qualifies, or may have qualified, as inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation.

For further public information, contact:
Pharming Group, Leiden, The Netherlands
Sijmen de Vries, CEO: T: +31 71 524 7400
Susanne Embleton, Investor Relations Manager: T: +31 71 524 7400 E: investor@pharming.com
FTI Consulting, London, UK
Victoria Foster Mitchell/Alex Shaw
T: +44 203 727 1000
FTI Consulting, USA
Jim Polson
T: +1 (312) 553-6730
LifeSpring Life Sciences Communication, Amsterdam, The Netherlands
Leon Melens
T: +31 6 53 81 64 27
E: pharming@lifespring.nl

Conference call dial-in information
Thursday October, 28, 2021 13:30CET/07:30ET
Please note, the Company will only take questions from dial-in attendees.

Dial-in details:

Netherlands (Local) 085 888 7233

United Kingdom 0800 640 6441

United Kingdom (Local) 020 3936 2999

United States (Local) 1 646 664 1960

All other locations +44 20 3936 2999

Access code: 147906

Webcast Link:
https://webcast.openbriefing.com/pharming-q321/

Pharming Group N.V.

Condensed Consolidated Interim Financial Statements in US Dollars (unaudited)

For the period ended 30 September 2021

  • Condensed consolidated statement of profit and loss

  • Condensed consolidated statement of comprehensive income

  • Condensed consolidated balance sheet

Appendix: Main condensed consolidated Interim Financial Statements reported in Euros (unaudited)

(This appendix is not part of the Condensed Consolidated Financial Statements)

  • Condensed consolidated statement of profit and loss in Euros

  • Condensed consolidated statement balance sheet in Euros

  • Condensed consolidated statement of cash flows in Euros

CONDENSED CONSOLIDATED STATEMENT OF PROFIT AND LOSS

For the 9-month period ended 30 September

Amounts in US$ ‘000

YTD 2021

YTD 2020

Revenues

146,101

151,874

Costs of sales

(15,500)

(16,566)

Gross profit

130,601

135,308

Other income

1,808

810

Research and development

(37,580)

(26,842)

OTL-105 in-licensing

(13,105)

0

General and administrative

(22,510)

(15,411)

Marketing and sales

(43,880)

(36,204)

Other Operating Costs

(117,075)

(78,457)

Operating profit

15,334

57,661

Fair value gain (loss) on revaluation derivatives

59

147

Other finance income

9,907

655

Other finance expenses

(4,466)

(20,614)

Finance cost net

5,500

(19,812)

Share of net profits in associates using the equity method

511

219

Profit before tax

21,345

38,068

Income tax credit (expense)

(7,412)

(9,212)

Profit for the year

13,933

28,856

Basic earnings per share (US$)

0.022

0.045

Fully-diluted earnings per share (US$)

0.018

0.039

CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

For the 9-month period ended 30 September

Amounts in US$ ‘000

YTD 2021

YTD 2020

Profit for the year

13,933

28,856

Currency translation differences

(10,506)

497

Fair value remeasurement investments

(1,475)

0

Items that may be subsequently reclassified to profit or loss

(11,981)

497

Other comprehensive income (loss), net of tax

(11,981)

497

Total comprehensive income (loss) for the year

1,952

29,353

CONDENSED CONSOLIDATED BALANCE SHEET

As at 30 September

Amounts in US$ ‘000

30 September
2021

31 December
2020

Non-current assets

Intangible assets

89,009

94,083

Property, plant and equipment

16,914

12,226

Right-of-use assets

20,982

9,427

Long-term prepayments

198

0

Deferred tax assets

21,473

31,877

Investments accounted for using the equity method

7,187

7,118

Investment in equity instruments designated as at FVTOCI

2,483

0

Restricted cash

481

510

Total non-current assets

158,727

155,241

Current assets

Inventories

25,098

21,157

Trade and other receivables

32,810

35,901

Restricted cash

981

995

Cash and cash equivalents

183,324

205,159

Total current assets

242,213

263,212

Total assets

400,940

418,453

Equity

Share capital

7,259

7,163

Share premium

453,476

444,940

Legal reserves

9,864

19,859

Accumulated deficit

(277,053)

(288,527)

Shareholders’ equity

193,546

183,435

Non-current liabilities

Convertible bonds

140,962

149,727

Lease liabilities

19,323

8,230

Other financial liabilities

386

212

Total non-current liabilities

160,671

158,169

Current liabilities

Convertible bonds

1,923

2,040

Derivative financial liabilities

54

181

Trade and other payables

42,151

47,666

Lease liabilities

2,595

1,962

Other financial liabilities

0

25,000

Total current liabilities

46,723

76,849

Total equity and liabilities

400,940

418,453

CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS in US Dollar

For the period ended 30 September

Amounts in US$ ‘000

YTD 2021

YTD 2020

Profit before tax

21,345

38,068

Non-cash adjustments:

Depreciation, amortization, impairment

6,867

5,741

Equity settled share based payments

5,706

2,365

Fair value gain (loss) on revaluation of derivatives

(59)

(148)

Other finance income

(9,907)

(655)

Other finance expense

4,466

20,616

Share of net profits in associates using the equity method

(511)

(220)

Other

272

2,489

Operating cash flows before changes in working capital

28,179

68,256

Changes in working capital:

Inventories

(3,941)

(2,159)

Trade and other receivables

3,092

(799)

Payables and other current liabilities

(5,514)

(1,979)

Restricted Cash

42

1,074

Total changes in working capital

(6,321)

(3,863)

Interest received

51

655

Income taxes paid

0

(2,741)

Net cash flows generated from (used in) operating activities

21,909

62,307

Capital expenditure for property, plant and equipment

(7,451)

(1,551)

Investment intangible assets

(1,544)

(374)

Investment in equity instruments designated as at FVTOCI

(4,589)

0

Acquisition of license

(1,593)

(9,523)

Net cash flows used in investing activities

(15,177)

(11,448)

Repayment on loans and borrowings

0

(56,273)

Payment on contingent consideration

(25,000)

(20,445)

Payment of lease liabilities

(2,476)

(1,489)

Proceeds of issued convertible bonds

0

138,312

Interests on loans and leases

(4,493)

(3,072)

Proceeds of equity and warrants

4,237

2,294

Net cash flows generated from (used in) financing activities

(27,732)

59,327

Increase (decrease) of cash

(21,000)

110,816

Exchange rate effects

(835)

(3,486)

Cash and cash equivalents at 1 January

205,159

74,348

Total cash and cash equivalents at 30 September

183,324

181,048

Appendix: Main Condensed Consolidated Financial Statements reported in Euro’s

These statements are not part of the original Interim Financial Statements. The original Interim Financial Statements are reported in US Dollars. In case of differences of interpretation between the Financial Statements in US dollars and the Financial Statements in Euros, the Financial Statements in US Dollars will prevail.

Exchange rates (USD:EUR) used:

Statement of income YTD 2020

1.1274

Statement of income YTD 2021

1,1982

Balance sheet at September 2020

1.1696

Balance sheet at December 2020

1.2280

Balance sheet at September 2021

1.1600

Cash flow YTD 2020

1.1274

Cash flow YTD 2021

1,1982

Cash balance as per 1 January 2020

1.1214

Cash balance as per 31 December 2020

1.2280

Cash balance as per 1 January 2021

1.2280

Cash balance as per 30 September 2021

1.1600

CONDENSED CONSOLIDATED STATEMENT OF PROFIT AND LOSS – EUR

For the 9-month period ended 30 September

Amounts in € ‘000

YTD 2021

YTD 2020

Revenues

121,934

134,714

Costs of sales

(12,936)

(14,694)

Gross profit

108,998

120,020

Other income

1,509

718

Research and development

(31,364)

(23,810)

OTL-105 in-licensing

(10,937)

0

General and administrative

(18,786)

(13,670)

Marketing and sales

(36,621)

(32,113)

Other Operating Costs

(97,709)

(69,593)

Operating profit

12,798

51,145

Fair value gain (loss) on revaluation derivatives

49

131

Other finance income

8,268

581

Other finance expenses

(3,728)

(18,285)

Finance cost net

4,589

(17,573)

Share of net profits in associates using the equity method

427

195

Profit before tax

17,815

33,767

Income tax expense

(6,188)

(8,171)

Profit for the year

11,627

25,596

Basic earnings per share (€)

0.018

0.040

Fully-diluted earnings per share (€)

0.015

0.035

CONDENSED CONSOLIDATED BALANCE SHEET – EUR

As at 30 September

Amounts in € ‘000

30 September
2021

31 December
2020

Non-current assets

Intangible assets

76,732

76,615

Property, plant and equipment

14,581

9,956

Right-of-use assets

18,088

7,676

Long-term prepayments

171

0

Deferred tax assets

18,510

25,957

Investments accounted for using the equity method

6,196

5,796

Investment in equity instruments designated as at FVTOCI

2,434

0

Restricted cash

415

415

Total non-current assets

136,833

126,415

Current assets

Inventories

21,636

17,229

Trade and other receivables

28,285

29,236

Restricted cash

846

810

Cash and cash equivalents

158,037

167,068

Total current assets

208,804

214,343

Total assets

345,637

340,758

Equity

Share capital

6,258

6,388

Share premium

390,928

396,799

Legal reserves

8,504

4,341

Accumulated deficit

(238,839)

(258,151)

Shareholders’ equity

166,851

149,377

Non-current liabilities

Convertible bonds

121,519

121,927

Lease liabilities

16,657

6,702

Other financial liabilities

333

173

Total non-current liabilities

138,509

128,802

Current liabilities

Convertible bonds

1,657

1,661

Derivative financial liabilities

47

147

Trade and other payables

36,337

38,816

Lease liabilities

2,237

1,598

Other financial liabilities

0

20,357

Total current liabilities

40,277

62,579

Total equity and liabilities

345,637

340,758

CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS – EUR

For the period ended 30 September

Amounts in €’000

YTD 2021

YTD 2020

Profit before tax

17.816

33.767

Non-cash adjustments:

Depreciation, amortization, impairment

5.730

5,092

Equity settled share-based payments

4.763

2,098

Fair value gain (loss) on revaluation of derivatives

-49

-131

Other finance income

-8.268

-581

Other finance expense

3.728

18,285

Share of net profits in associates using the equity method

-427

-195

Other

226

2,208

Operating cash flows before changes in working capital

23.519

60,543

Changes in working capital:

Inventories

-3,289

-1,915

Trade and other receivables

2,580

-709

Payables and other current liabilities

-4,602

-1,755

Restricted Cash

35

1,012

Total changes in working capital

-5,276

-3,367

Interest received

43

581

Income taxes paid

0

-2,431

Net cash flows generated from (used in) operating activities

18,286

55,326

Capital expenditure for property, plant and equipment

-6,219

-1,376

Investment intangible assets

-1,289

-332

Investment in equity instruments designated as at FVTOCI

-3,830

0

Acquisition of license

-1,330

-8,447

Net cash flows used in investing activities

-12,668

-10,155

Repayment on loans and borrowings

0

-49,914

Payment on contingent consideration

-20,865

-18,135

Payment of lease liabilities

-2,067

-1,321

Proceeds of issued convertible bonds

0

122,682

Interests on loans and leases

-3,750

-2,725

Proceeds of equity and warrants

3,536

2,035

Net cash flows generated from (used in) financing activities

-23,146

52,622

Increase (decrease) of cash

-17,528

97,793

Exchange rate effects

8,497

-9,297

Cash and cash equivalents at 1 January

167,068

66,299

Total cash and cash equivalents at 30 September

158,037

154,795

Logo – https://mma.prnewswire.com/media/1454235/Pharming_Group_NV_Logo.jpg



Source link

Share:

Share on facebook
Facebook
Share on twitter
Twitter
Share on pinterest
Pinterest
Oliver Bolt

Oliver Bolt

On Key

Related Posts

Check All Features, Benefits Here

Bajaj Housing Finance offers home loans at a rate of 6.70 per cent Bajaj Housing Finance reduced its home loan interest